Hologic, Inc. (HOLX) is a global medical technology company with a market cap of $16.7 billion, focused on improving women’s health. HOLX stock has outperformed the S&P 500 Index over the past 52 weeks, with a 16.2% increase. However, YTD, the stock has slightly lagged behind with a 1.7% return. Following its Q1 2026 results, Hologic saw a marginal decrease in shares due to adjusted EPS of $1.04 and revenue of $1.05 billion, both below expectations. Analysts expect HOLX’s adjusted EPS to grow 4.9% year-over-year to $4.47 for fiscal year 2026, with a consensus rating of “Hold.” The mean price target is $75.58, with a high of $79, suggesting a 5.3% potential upside.

Read more at Barchart: Is Wall Street Bullish or Bearish on Hologic Stock?